Revolution’s RAS inhibitor pipeline posts more pancreatic cancer trial wins
The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic cancer.
03 July 2026
03 July 2026
The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic cancer.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.